- Identification and assessment of first-in-class molecular targets, with a particular focus on earlystage programs for which clinical utility has yet to be
evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for pain therapeutics, and benchmarking of deals involving first-in-class versus non-first-in-class-products.
Reasons to buy
- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the pain markets in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
Download sample Copy of This Report at: http:// www. radiantinsights. com / research / frontier-pharma-chronic-acute-andneuropathic-pain-gpcr-and-nerve-growth / request-sample
- Analyze the pain pipeline, stratified by pain subtype, stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the pain deals landscape by analyzing trends in licensing and co-development deals, and producing a list of pain therapeutics that are not yet involved in deals and may be potential investment opportunities.
Table of Contents 1 Table of Contents 2 1.1 List of Tables 2 1.2 List of Figures 3
2 Executive Summary 4
Follow Us: